We thank Jiang et al. for their interest and their comments to our systematic review and meta-analysis of the prognostic value on p16 and p53 expression for survival after vulvar cancer.
Jiang et al. state that we have included duplicated studies in our meta-analysis and specifically mention two references -both by (Sznurkowski et al., 2016 (Sznurkowski et al., , 2017 . As described in our paper (Sand et al., 2019) in the paragraph "Search results", these studies have indeed overlapping study populations, but report different survival outcomes (overall survival and disease free survival, respectively), and were therefore both included in the paper. However, only one of the studies (Sznurkowski et al., 2016) was included in the calculated pooled estimate on overall survival according to p16 status. In our paper, overlapping study populations have systematically been identified and excluded as appropriate, therefore, to the best of our knowledge, no duplicate studies have been included in the meta-analysis.
In addition, we evaluated the quality of all studies based on Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) (Altman et al., 2012; McShane et al., 2005) . The evaluation criteria are included in supplementary tables and the scores are included in Tables 1 and 3 in the main text (Sand et al., 2019) . Most studies were of good quality, and we did not exclude any studies based on quality score alone. Finally, we agree with Jiang et al. about the importance of describing inclusion and exclusion criteria.
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